Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis

Hyo Young Lee, Dae Won Jun, Hyun Jung Kim, Hyunwoo Oh, Waqar Khalid Saeed, Hyeong Sik Ahn, Ramsey C. Cheung, Mindie H. Nguyen

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background/Aims: A number of clinical trials reported varying effects of cholesterol lowering agents in nonalcoholic fatty liver disease (NAFLD) patients. We, therefore, assessed the changes in hepatic steatosis and NAFLD activity score (NAS) after treatment with cholesterol lowering agents in NAFLD patients by meta-analysis. Methods: The Cochrane Library, the MEDLINE, and the Embase databases were searched until May 2015, without any language restrictions, for randomized controlled trials (RCTs) and nonrandomized studies (NRSs). Additional references were obtained from review of bibliography of relevant articles. The quality of evidence was assessed using the grading of recommendations assessment, development and evaluation guidelines. Results: Three RCTs (n = 98) and two NRSs (n = 101) met our study inclusion criteria (adult, NAFLD, liver biopsy). Liver biopsy was performed in all five studies, but only the three studies reported NAS. Ezetimibe significantly decreased NAS (standardized mean difference [SMD], –0.30; 95% confidence interval [CI], –0.57 to –0.03) but not hepatic steatosis in RCT (SMD, –0.1; 95% CI, –0.53 to 0.32), while the effect was significant for both NAS and intrahepatic content in NRSs (SMD, –3.0; 95% CI, –6.9 to 0.91). Conclusions: Ezetimibe decreased NAS without improving hepatic steatosis.

Original languageEnglish
Pages (from-to)296-304
Number of pages9
JournalKorean Journal of Internal Medicine
Volume34
Issue number2
DOIs
Publication statusPublished - 2019 Mar 1

Keywords

  • Ezetimibe
  • Hydroxymethylglu-taryl-CoA reductase inhibitors
  • Meta-analysis
  • Non-alcoholic fatty liver disease

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis'. Together they form a unique fingerprint.

  • Cite this